Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia

被引：46

作者：

Jo, Helen E. ^{[1
,2
]}

Troy, Lauren K. ^{[1
,2
]}

Keir, Gregory ^{[3
]}

Chambers, Daniel C. ^{[4
]}

Holland, Anne ^{[5
]}

Goh, Nicole ^{[4
,7
]}

Wilsher, Margaret ^{[11
]}

De Boer, Sally ^{[11
]}

Moodley, Yuben ^{[8
]}

Grainge, Christopher ^{[9
]}

Whitford, Helen ^{[6
]}

Chapman, Sally ^{[10
]}

Reynolds, Paul N. ^{[10
]}

Glaspole, Ian ^{[6
]}

Beatson, David

Jones, Leonie ^{[9
]}

Hopkins, Peter ^{[4
]}

Corte, Tamera J. ^{[2
]}

机构：

[1] Royal Prince Alfred Hosp, Dept Resp Med, Missenden Rd, Sydney, NSW 2050, Australia

[2] Univ Sydney, Fac Med, Sydney, NSW, Australia

[3] Princess Alexandra Hosp, Dept Resp Med, Brisbane, Qld, Australia

[4] Prince Charles Hosp, Dept Resp Med, Brisbane, Qld, Australia

[5] Alfred Hosp, Dept Physiotherapy, Melbourne, Vic, Australia

[6] Alfred Hosp, Dept Resp Med, Melbourne, Vic, Australia

[7] Austin Hosp, Dept Resp Med, Melbourne, Vic, Australia

[8] Fiona Stanley Hosp, Dept Resp Med, Perth, WA, Australia

[9] John Hunter Hosp, Dept Resp Med, Newcastle, NSW, Australia

[10] Royal Adelaide Hosp, Dept Resp Med, Adelaide, SA, Australia

[11] Auckland Dist Hlth Board, Dept Resp Med, Auckland, New Zealand

来源：

RESPIROLOGY | 2017年 / 22卷 / 07期

关键词：

idiopathic pulmonary fibrosis; interstitial lung disease; nintedanib; pirfenidone; treatment; PLACEBO-CONTROLLED TRIAL; OBSTRUCTIVE SLEEP-APNEA; QUALITY-OF-LIFE; NONSPECIFIC INTERSTITIAL PNEUMONIA; ACID GASTROESOPHAGEAL-REFLUX; DOMICILIARY OXYGEN-THERAPY; FORCED VITAL CAPACITY; PALLIATIVE CARE; DOUBLE-BLIND; ACUTE EXACERBATION;

D O I：

10.1111/resp.13146

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial lung disease (ILD) of unknown aetiology with a median survival of only 2-5 years. It is characterized by progressive dyspnoea and worsening lung function, ultimately resulting in death. Until recently, there were no effective therapies for IPF; however, with the publication of two landmark clinical trials in 2014, the anti-fibrotic therapies, nintedanib and pirfenidone, have gained widespread approval. This position paper aims to highlight the current evidence for the treatment of IPF, with particular application to the Australian and New Zealand population. We also consider areas in which evidence is currently lacking, especially with regard to the broader IPF severity spectrum and treatment of co-morbid conditions. The utility of non-pharmacological therapies including pulmonary rehabilitation, oxygen as well as symptom management thought to be important in the holistic care of IPF patients are also discussed.

引用

页码：1436 / 1458

页数：23

共 185 条

[1] Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial [J].

Abernethy, Amy P. ;

McDonald, Christine F. ;

Frith, Peter A. ;

Clark, Katherine ;

Herndon, James E., II ;

Marcello, Jennifer ;

Young, Iven H. ;

Bull, Janet ;

Wilcock, Andrew ;

Booth, Sara ;

Wheeler, Jane L. ;

Tulsky, James A. ;

Crockett, Alan J. ;

Currow, David C. .

LANCET, 2010, 376 (9743) :784-793

[2] Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea [J].

Abernethy, AP ;

Currow, DC ;

Frith, P ;

Fazekas, BS ;

McHugh, A ;

Bui, C .

BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :523-526

[3] End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study [J].

Ahmadi, Zainab ;

Wysham, Nicholas G. ;

Lundstrom, Staffan ;

Janson, Christer ;

Currow, David C. ;

Ekstrom, Magnus .

THORAX, 2016, 71 (06) :510-516

[4] Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function [J].

Albera, Carlo ;

Costabel, Ulrich ;

Fagan, Elizabeth A. ;

Glassberg, Marilyn K. ;

Gorina, Eduard ;

Lancaster, Lisa ;

Lederer, David J. ;

Nathan, Steven D. ;

Spirig, Dominique ;

Swigris, Jeff J. .

EUROPEAN RESPIRATORY JOURNAL, 2016, 48 (03) :843-851

[5] Australian and New Zealand Pulmonary Rehabilitation Guidelines [J].

Alison, Jennifer A. ;

McKeough, Zoe J. ;

Johnston, Kylie ;

McNamara, Renae J. ;

Spencer, Lissa M. ;

Jenkins, Sue C. ;

Hill, Catherine J. ;

McDonald, Vanessa M. ;

Frith, Peter ;

Cafarella, Paul ;

Brooke, Michelle ;

Cameron-Tucker, Helen L. ;

Candy, Sarah ;

Cecins, Nola ;

Chan, Andrew S. L. ;

Dale, Marita T. ;

Dowman, Leona M. ;

Granger, Catherine ;

Halloran, Simon ;

Jung, Peter ;

Lee, Annemarie L. ;

Leung, Regina ;

Matulick, Tamara ;

Osadnik, Christian ;

Roberts, Mary ;

Walsh, James ;

Wootton, Sally ;

Holland, Anne E. .

RESPIROLOGY, 2017, 22 (04) :800-819

[6]

[Anonymous], 1980, Ann Intern Med, V93, P391

[7]

[Anonymous], COCHRANE DATABASE SY

[8]

[Anonymous], 2014, NEW ENGL J MED, V370, P2093

[9]

[Anonymous], 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00

[10] Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis [J].

Arai, Toru ;

Inoue, Yoshikazu ;

Sasaki, Yumiko ;

Tachibana, Kazunobu ;

Nakao, Keiko ;

Sugimoto, Chikatoshi ;

Okuma, Tomohisa ;

Akira, Masanori ;

Kitaichi, Masanori ;

Hayashi, Seiji .

RESPIRATORY INVESTIGATION, 2014, 52 (02) :136-143

← 1 2 3 4 5 6 7 8 9 10 →